The Latest Developments in Cancer Care --
Close to Home

The North Central Cancer Treatment Group (NCCTG) is a national clinical research group sponsored by the National Cancer Institute. NCCTG consists of a network of cancer specialists at community clinics, hospitals and medical centers in the United States and Canada. The research base for NCCTG is located at Mayo Clinic in Rochester, Minn.

NCCTG is dedicated to bringing clinical trials with promising new cancer therapies to communities where patients live. NCCTG specializes in researching methods of treating and preventing cancer, and in researching methods to alleviate the side effects of cancer and cancer treatments.

STATEMENT REGARDING DISCONTINUATION OF ARM 2 ALTTO BREAST CANCER CLINICAL TRIAL

The leadership of the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation study (ALTTO) today announced that it will discontinue Arm 2 of the international, phase III clinical trial of two targeted therapies for patients with early stage HER2?positive breast cancer. In this trial all patients received other treatments as part of standard of care (such as chemotherapy, radiation, anti?estrogens) after surgery, and were randomized to one of four different ways to receive the two types of anti?HER2 therapy trastuzumab or lapatinib. The change in status of this trial directly affects patients assigned to Arm 2, those patients receiving lapatinib alone.

• Frequently Asked Questions for Patients

Updates on Restructuring of the National Cancer Clinical Trials System

• Fall Alliance Group Meeting – The Alliance for Clinical Trials in Oncology (ACTION or the Alliance) will hold its first group meeting on Nov 17 - 19, 2011, in Chicago. For Meeting and registration information, visit the Alliance website at http://www.allianceforclinicaltrialsinoncology.org.
• Alliance Membership Applications – All current members of the North Central Cancer Treatment Group (NCCTG), the Cancer and Leukemia Group B (CALGB), and the American College of Surgeons Oncology Group (ACOSOG) will be required to apply to the Alliance before the end of the transition period in 2014. Beginning September 1, 2011, applications will be accepted for current members and new members.
• Alliance Newsletter: ACTION News – Published twice each month, ACTION News will provide up to date information on Alliance activities.
  • ACTION News – Summer 2011
• Membership Applications/Instructions – To obtain a membership application and instructions, visit the Alliance website at http://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FBecome-Member
• Alliance Membership Inquiries – For additional membership information or questions on completing the membership application, contact Marcia Kelly, Membership Coordinator by phone at 773-83-7676 or by e-mail at marciak@uchicago.edu

This section provides information on National Cancer Institute (NCI) initiatives to restructure the National Cancer Clinical Trials System and updates on NCCTG initiatives to respond to these new directives and collaborate with the Cancer and Leukemia Group B (CALGB) and the American College of Surgeons Oncology Group (ACOSOG) to form a new cooperative group organization. Click here for more details.

NCCTG
Operations Office
200 First Street SW
Rochester, MN 55905
Phone: 507-538-4426
Fax: 507-538-0906
E-mail: ncctg@mayo.edu

© Copyright 2013, NCCTG